Partner with us

At the Neuroscience Institute we understand the vital link between research and industry application.

Brain scans

We are proud to work in collaboration with a number of charities, global institutes and leading global organisations and seek new and exciting opportunities to further enhance our translational research.

By working together we believe we can find novel solutions to the biggest neurological challenges and help to change lives.

The Neuroscience Institute
University of Sheffield
385a Glossop Road
Sheffield
South Yorkshire
S10 2HQ
neuroscience@sheffield.ac.uk


Collaborations with business and industry

Discover how our pioneering partnerships are accelerating discoveries and understanding.

Scientist undertaking experiment in lab

Pfizer

A consortium led by Pfizer and the University of Sheffield will standardise and accelerate the development of Advanced Therapy Medicinal Products (ATMPs), allowing potentially transformative treatments to reach patients sooner.

Accelerating the development of Advanced Therapies

Mitochondria - microbiology 3d illustration

Nanna Therapeutics

This partnership will advance mitochondrial drug discovery research for neurodegenerative diseases by bringing together resources and expertise in compounds with our knowledge on drug screenings in patient derived-cells.

Treating neurodegenerative diseases by boosting mitochondria

Scientist working in drug screening lab

Aclipse Therapeutics

Researchers have been awarded a drug development grant to progress a disease-modifying drug candidate - M102 - into first in-human trials for patients with motor neuron disease (MND).

Taking a potential treatment for MND into clinical trials

Scientist using petri dish

Quell Therapeutics

Our researchers have agreed a new partnership with Quell Therapeutics to accelerate Quell’s engineered Treg cell therapy platform for use in the treatment of neuroinflammatory diseases.

Progressing treatments for neuroinflammatory diseases

Neurotransmitters

FORMA Therapeutics

This collaboration focuses on using patient cells to understand the complex biology underpinning Parkinson’s and motor neuron disease (MND) and to harness this technology for novel drug discovery.

Accelerating treatments for Parkinson's

Medical research pharmaceutical factory laboratory

Keapstone Therapeutics

The University of Sheffield and Parkinson’s UK launched a new virtual biotech company as part of a pioneering research programme. Keapstone Therapeutics combines our world-leading research with funding and expertise from the charity to help develop a revolutionary drug for Parkinson’s disease.

World-first partnership to develop new drugs for Parkinson’s

Neurons

Resagen: Therapy for damaged motor neurons

Our extensive research data has provided promising proof of concept for Resagen, a potential gene therapy product for patients with spinal muscular atrophy (SMA). Applying this research could lead to a safe and effective treatment. Ongoing work continues with the hope of starting clinical trials in the near future.

Towards a safe and effective treatment